Proactive Investors - Run By Investors For Investors

hVIVO lands two new contracts worth £9mln

The specialist in human disease models said it is in talks with pharmaceutical companies over further deals
petrie dish
An order has come in for a further two respiratory syncytial virus human challenge studies

hVIVO PLC (AIM:HVO), a specialist in human disease models, said it is in talks with pharmaceutical companies over further deals after landing new contracts worth £9mln.

Updating the market, it said it will provide an unnamed “leading global biopharmaceutical company” with two respiratory syncytial virus (RSV) human challenge studies. This follows last month’s £11.9mln RSV agreement.

Contagious, respiratory syncytial virus causes the common cold, for which there is no effective cure.

Revenue impact next year

The revenue impact of the latest deal will be felt mainly next year.

“The recent significant new contract wins reinforce our leading position in human disease models based upon viral and allergen challenge and are a testament to our industry leading RSV-human challenge model,” said chairman, Dr Trevor Phillips.

“We have the strongest sales pipeline we have had for several years.

“We remain actively engaged in several discussions with other pharmaceutical companies for contracting studies across our current challenge portfolio, including allergen, asthma, human rhinovirus, influenza and RSV.”

High levels of demand

Phillips said hVIVO continued to experience “high levels of interest” from global pharma companies interested in new challenge models for RSV, asthma and chronic obstructive pulmonary disease.

“With the significant demand for our services across the entire portfolio, we expect to convert a growing number of these opportunities into contracts that will further validate our service offerings and enhance our revenue in 2019 and beyond," he added.

In a separate announcement, hVIVO said former chairman Jaime Ellertson is leaving the board with immediate effect.

The shares rose 10% at 64.60p, valuing the business at just shy of £51mln.

--- Adds share price ---


View full HVO profile View Profile

hVIVO PLC Timeline

September 02 2016

Related Articles

Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use